Key Points
- CEO Scott Hutton sold 1,490 shares on Feb. 23 at an average price of $12.78 for $19,042.20, leaving him with 48,767 shares (a 2.96% reduction in his position).
- Hutton also sold 3,559 shares on Feb. 10 at $10.08 and 970 shares on Jan. 16 at $8.15, signaling multiple insider sales over recent months.
- Biodesix shares opened at $12.77 with a market cap of about $101.65 million and a 1‑year range of $3.44–$19.13, while analysts have a consensus rating of "Moderate Buy" and an average price target of $32.50.
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) CEO Scott Hutton sold 1,490 shares of the stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $12.78, for a total transaction of $19,042.20. Following the completion of the sale, the chief executive officer owned 48,767 shares of the company's stock, valued at approximately $623,242.26. The trade was a 2.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Scott Hutton also recently made the following trade(s):
- On Tuesday, February 10th, Scott Hutton sold 3,559 shares of Biodesix stock. The shares were sold at an average price of $10.08, for a total value of $35,874.72.
- On Friday, January 16th, Scott Hutton sold 970 shares of Biodesix stock. The shares were sold at an average price of $8.15, for a total value of $7,905.50.
Biodesix Price Performance
Shares of NASDAQ:BDSX opened at $12.77 on Tuesday. The firm has a market capitalization of $101.65 million, a PE ratio of -2.30 and a beta of 0.66. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 41.11. Biodesix, Inc. has a 1-year low of $3.44 and a 1-year high of $19.13. The business's 50 day moving average is $9.02 and its 200-day moving average is $8.21.
Analyst Upgrades and Downgrades
BDSX has been the subject of a number of recent research reports. Canaccord Genuity Group restated a "buy" rating and issued a $20.00 price objective on shares of Biodesix in a research note on Tuesday, February 17th. Weiss Ratings reissued a "sell (e+)" rating on shares of Biodesix in a research report on Monday, December 22nd. Finally, Wall Street Zen raised Biodesix from a "sell" rating to a "hold" rating in a report on Saturday, November 8th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $32.50.
View Our Latest Analysis on BDSX
Institutional Investors Weigh In On Biodesix
Large investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in Biodesix by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company's stock valued at $289,000 after purchasing an additional 2,235 shares during the last quarter. State Street Corp increased its holdings in shares of Biodesix by 15.6% during the fourth quarter. State Street Corp now owns 17,802 shares of the company's stock worth $121,000 after buying an additional 2,400 shares in the last quarter. Cetera Investment Advisers bought a new position in shares of Biodesix in the fourth quarter valued at approximately $68,000. Monashee Investment Management LLC boosted its holdings in shares of Biodesix by 12.3% in the 4th quarter. Monashee Investment Management LLC now owns 112,344 shares of the company's stock worth $764,000 after acquiring an additional 12,348 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in shares of Biodesix in the 3rd quarter worth approximately $113,000. Institutional investors own 20.96% of the company's stock.
Biodesix Company Profile
(
Get Free Report)
Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.
The company's flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
